An Early Phase 1 interventional study of Rivaroxaban 10 MG Oral Tablet [Xarelto] in Combined Anticoagulation and Antithrombotic Therapy and PAD - Peripheral Arterial Disease, sponsored by Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi. Status unknown at 1 site in Pakistan. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-03.
Sponsored by Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing rivaroxaban in Peripheral Arterial Disease — 3 open to participants now, 3 under way, none of them phase 3. Rivaroxaban · Peripheral Arterial Disease.
Among the 13 studies testing rivaroxaban in Peripheral Arterial Disease, this one is the 11th largest by planned enrollment, is one of 3 that started in 2021, is one of 2 in phase 1, and was the 8th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →3 of the 13 studies testing rivaroxaban in Peripheral Arterial Disease are open now, in 3 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Science Valley Research Institute · Sites in Brazil
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 100 across the 13 interventional studies. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 10 most frequent:
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi has 1 study filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
2 of the studies testing rivaroxaban in Peripheral Arterial Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613840Massachusetts General HospitalPersonalizing Thromboprophylaxis for Patients With Peripheral Artery Disease | 2027-04-29 |
| NCT07796217Seoul National University Bundang HospitalComparison of Clopidogrel-based Antiplatelet Agent Treatment and Aspirin Plus Low Dose Rivaroxaban Therapy | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing rivaroxaban in Peripheral Arterial Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
EFFECTIVENESS OF COMBINED ANTICOAGULATION AND ANTITHROMBOTIC THERAPY VS ANTITHROMBOTIC THERAPY ALONE AFTER LOWER EXTREMITY REVASCULARIZATION FOR PERIPHERAL ARTERIAL DISEASE.
Anticoagulation and antithrombotic therapy is a crucial part of PAD management as it prolongs the patecy of grafts in open surgical revascularization procedures so its proper dosage and duration without increasing risks to the patient and maximizing the benefits is very important.
Currently literature in Pakistan regarding this problem couldn't be found so this study would help assessing the outcomes of anticoagulation and antithrombotic therapy in this population with respect to treatment options available and presentation variability of the peripheral arterial disease. Patients with PAD would be enrolled for 6 months and would be followed upto 12 months and then upto 24 months.
Eligible subjects will be randomized 1:1 to receive either rivaroxaban 5 mg twice daily plus aspirin 75 mg once daily or rivaroxaban-matching placebo twice daily plus aspirin 75 mg once daily stratified by type of procedure; the treatment assignment will be double-blinded. Randomization and study treatment will begin as soon as possible but no later than 10 days after a successfull lower extremity revascularization.
Patients will be prohibited from taking any additional antithrombotic therapy other drugs, including anticoagulants, doses of aspirin >100 mg daily, vorapaxar, ticagrelor, prasugrel, or cilostazol. Enrolled subjects will be having symptomatic PAD defined by evidence of an abnormal ankle-brachial index ≤0.80 in either limb with an anatomy of occlusive disease of involving segments. Subjects would be randomized who had undergone a technically successful endovascular, hybrid, or surgical LER within 10 days and had achieved adequate hemostasis before randomization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
group A patients would be receiving rivaroxaban and aspirin as experimental group to see the efficacy of rivaroxaban in peripheral arterial disease.
Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto]
group B patients would be those receiving traditional antithrombotic therapy as usually given n Peripheral Arterial Disease.
Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto]
rivaroxaban has shown improved results after revascularization for PAD in terms of limb survival
ALI
acute limb ischemia
Time frame: upto 1 year
major amputation for vascular reasons
any type of major amputation after revascularivation for PAD
Time frame: upto 1 year
MI
myocardial infarction
Time frame: upto 1 year
ischemic stroke
ischemic stroke
Time frame: upto 1 year
cardiovascular death
death because of cardiovascular events
Time frame: upto 1 year
thrombolysis in myocardial infarction(TIMI)major bleeding
combined therapy effect may result in increased bleeding tendency
Time frame: 2, 30, 180 and 365 days
Plan to share: Yes — title
Supporting information: Study protocol
Time frame: 6 months from start of study
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for Dec 2022, 17 months after the start.
Of 26 phase 1 interventional studies under Peripheral Arterial Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi